Company intelligence / Profile preview
Kanpecia Biotech LLC
Lawrence, Kansas, United Stateskanpecia.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
KaB-103 has shown early and improved hair growth in rodent models compared to both controls and Minoxidil. Early toxicity studies indicate high levels of systemic KaB-103 has not shown adverse effects in rats.[1]
- Therapeutic areas
- OncologyDermatology
- Modalities
- Topical medication
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Kansas (co-owner of technology)
Beyond the preview
Go deeper on Kanpecia Biotech LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kanpecia Biotech LLC.